Statin Therapy and Risk of Fracture: Results From the JUPITER Randomized Clinical Trial | Cardiology | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
McFarlane  SI, Muniyappa  R, Shin  JJ, Bahtiyar  G, Sowers  JR.  Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link?  Endocrine. 2004;23(1):1-10.PubMedGoogle ScholarCrossref
Sennerby  U, Melhus  H, Gedeborg  R,  et al.  Cardiovascular diseases and risk of hip fracture.  JAMA. 2009;302(15):1666-1673.PubMedGoogle ScholarCrossref
Greenblatt  MB, Shim  J-H.  Osteoimmunology: a brief introduction.  Immune Netw. 2013;13(4):111-115.PubMedGoogle ScholarCrossref
D’Amelio  P, Isaia  G, Isaia  GC.  The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.  J Endocrinol Invest. 2009;32(4)(suppl):6-9.PubMedGoogle Scholar
Baud’huin  M, Lamoureux  F, Duplomb  L, Rédini  F, Heymann  D.  RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases.  Cell Mol Life Sci. 2007;64(18):2334-2350.PubMedGoogle ScholarCrossref
Mundy  G, Garrett  R, Harris  S,  et al.  Stimulation of bone formation in vitro and in rodents by statins.  Science. 1999;286(5446):1946-1949.PubMedGoogle ScholarCrossref
Cummings  SR, Bauer  DC.  Do statins prevent both cardiovascular disease and fracture?  JAMA. 2000;283(24):3255-3257.PubMedGoogle ScholarCrossref
Chan  KA, Andrade  SE, Boles  M,  et al.  Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women.  Lancet. 2000;355(9222):2185-2188.PubMedGoogle ScholarCrossref
Scranton  RE, Young  M, Lawler  E, Solomon  D, Gagnon  D, Gaziano  JM.  Statin use and fracture risk: study of a US veterans population.  Arch Intern Med. 2005;165(17):2007-2012.PubMedGoogle ScholarCrossref
Wang  PS, Solomon  DH, Mogun  H, Avorn  J.  HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients.  JAMA. 2000;283(24):3211-3216.PubMedGoogle ScholarCrossref
Meier  CR, Schlienger  RG, Kraenzlin  ME, Schlegel  B, Jick  H.  HMG-CoA reductase inhibitors and the risk of fractures.  JAMA. 2000;283(24):3205-3210.PubMedGoogle ScholarCrossref
Helin-Salmivaara  A, Korhonen  MJ, Lehenkari  P,  et al.  Statins and hip fracture prevention—a population based cohort study in women.  PLoS One. 2012;7(10):e48095. PubMedGoogle ScholarCrossref
van Staa  TP, Wegman  S, de Vries  F, Leufkens  B, Cooper  C.  Use of statins and risk of fractures.  JAMA. 2001;285(14):1850-1855.PubMedGoogle ScholarCrossref
LaCroix  AZ, Cauley  JA, Pettinger  M,  et al.  Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women’s Health Initiative Observational Study.  Ann Intern Med. 2003;139(2):97-104.PubMedGoogle ScholarCrossref
Lupattelli  G, Scarponi  AM, Vaudo  G,  et al.  Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women.  Metabolism. 2004;53(6):744-748.PubMedGoogle ScholarCrossref
Edwards  CJ, Hart  DJ, Spector  TD.  Oral statins and increased bone-mineral density in postmenopausal women.  Lancet. 2000;355(9222):2218-2219.PubMedGoogle ScholarCrossref
Liu  J, Zhu  L-P, Yang  X-L, Huang  H-L, Ye  D-Q.  HMG-CoA reductase inhibitors (statins) and bone mineral density: a meta-analysis.  Bone. 2013;54(1):151-156.PubMedGoogle ScholarCrossref
El-Sohemy  A.  Statin drugs and the risk of fracture.  JAMA. 2000;284(15):1921-1922.PubMedGoogle Scholar
Reid  IR, Hague  W, Emberson  J,  et al.  Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial.  Lancet. 2001;357(9255):509-512.PubMedGoogle ScholarCrossref
Bauer  DC, Mundy  GR, Jamal  SA,  et al.  Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials.  Arch Intern Med. 2004;164(2):146-152.PubMedGoogle ScholarCrossref
Ridker  PM, Danielson  E, Fonseca  FAH,  et al; JUPITER Study Group.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.  N Engl J Med. 2008;359(21):2195-2207.PubMedGoogle ScholarCrossref
Glynn  RJ, MacFadyen  JG, Ridker  PM.  Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER study.  Clin Chem. 2009;55(2):305-312.PubMedGoogle ScholarCrossref
Ridker  PM, MacFadyen  J, Libby  P, Glynn  RJ.  Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).  Am J Cardiol. 2010;106(2):204-209.PubMedGoogle ScholarCrossref
Heart Protection Study Collaborative Group.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.  Lancet. 2002;360(9326):7-22.PubMedGoogle ScholarCrossref
Yue  J, Zhang  X, Dong  B, Yang  M.  Statins and bone health in postmenopausal women: a systematic review of randomized controlled trials.  Menopause. 2010;17(5):1071-1079.PubMedGoogle ScholarCrossref
Dormuth  CR, Patrick  AR, Shrank  WH,  et al.  Statin adherence and risk of accidents: a cautionary tale.  Circulation. 2009;119(15):2051-2057.PubMedGoogle ScholarCrossref
Glynn  RJ, Schneeweiss  S, Wang  PS, Levin  R, Avorn  J.  Selective prescribing led to overestimation of the benefits of lipid-lowering drugs.  J Clin Epidemiol. 2006;59(8):819-828.PubMedGoogle ScholarCrossref
Nakamura  K, Saito  T, Kobayashi  R,  et al.  C-reactive protein predicts incident fracture in community-dwelling elderly Japanese women: the Muramatsu study.  Osteoporos Int. 2011;22(7):2145-2150.PubMedGoogle ScholarCrossref
Pasco  JA, Kotowicz  MA, Henry  MJ,  et al.  High-sensitivity C-reactive protein and fracture risk in elderly women.  JAMA. 2006;296(11):1353-1355.PubMedGoogle ScholarCrossref
Schett  G, Kiechl  S, Weger  S,  et al.  High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study.  Arch Intern Med. 2006;166(22):2495-2501.PubMedGoogle ScholarCrossref
Original Investigation
February 2015

Statin Therapy and Risk of Fracture: Results From the JUPITER Randomized Clinical Trial

Author Affiliations
  • 1Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York
  • 2Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden
  • 3Division of Preventive Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 4Division of Rheumatology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 5Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
JAMA Intern Med. 2015;175(2):171-177. doi:10.1001/jamainternmed.2014.6388

Importance  Osteoporosis and cardiovascular disease may share common biological pathways, with inflammation playing a role in the development of both. Although observational studies have suggested that statin use is associated with a lower risk of fractures, randomized trial data addressing this issue are scant.

Objective  To determine whether statin therapy reduces the risk of fracture and, in a secondary analysis, whether baseline levels of the inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) are associated with the risk of fracture.

Design, Setting, and Participants  The JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial was an international, randomized, double-blind, placebo-controlled study enrolling 17 802 men older than 50 years and women older than 60 years with hs-CRP level of at least 2 mg/L. Participants were screened from 2003 to 2006 and observed prospectively for up to 5 years (median follow-up, 1.9 years).

Intervention  Rosuvastatin calcium, 20 mg daily, or placebo.

Main Outcomes and Measures  Incident fracture was a prespecified secondary end point of JUPITER. Fractures were confirmed by radiographs, computed tomography, bone scan, or other methods. Cox proportional hazards models were used to calculate hazard ratios (HRs) and associated 95% confidence intervals for the risk of fracture according to randomized treatment assignment, as well as increasing tertiles of hs-CRP, controlling for potential confounders.

Results  During the study, 431 incident fractures were reported and confirmed. Among participants allocated to rosuvastatin, 221 fractures were confirmed, compared with 210 among those allocated to placebo, such that the incidence of fracture in the rosuvastatin and placebo groups was 1.20 and 1.14 per 100 person-years, respectively (adjusted HR, 1.06 [95% CI, 0.88-1.28]; P = .53). Overall, increasing baseline hs-CRP level was not associated with an increased risk of fractures (adjusted HR for each unit increase in hs-CRP tertile, 1.06 [95% CI, 0.94-1.20]; P for trend, .34).

Conclusions and Relevance  Among men and women with elevated hs-CRP level enrolled in a large trial of rosuvastatin therapy for cardiovascular disease, statin therapy did not reduce the risk of fracture. Higher baseline hs-CRP level was not associated with an increased risk of incident fracture.

Trial Registration Identifier: NCT00239681